Key result
Fenofibrate attenuated the correlation between reduced heart rate variability (SDNN) and coronary artery disease progression observed in the placebo group (r=0.50, P<0.01 vs not significant).
Why the study?
Does fenofibrate compared to placebo affect the temporal changes in cardiovascular autonomic regulation and its association with CAD progression in type II diabetic patients?
RCT (n=53)
Randomized
No
Does fenofibrate compared to placebo affect the temporal changes in cardiovascular autonomic regulation and its association with CAD progression in type II diabetic patients?
p-value: p=<0.001
Cardiovascular autonomic regulation deteriorates rapidly over 3 years in type II diabetic patients with CAD, and this impairment correlates with CAD progression, an association that may be attenuated by fenofibrate.
Fenofibrate may blunt HRV-CAD progression link in T2DM; extends RCT substudy data on autonomic-CAD interplay.
AIM: This research was designed to study the temporal changes in cardiovascular autonomic regulation, assessed by 24-hour heart rate (HR) variability, and the possible relation of changes in HR variability to cardiovascular risk factors and progression of coronary artery disease (CAD) among type II diabetic subjects. METHOD: In a single-center substudy of The Diabetes Atherosclerosis Intervention Study (DAIS), 53 patients assigned to fenofibrate (n = 26) or placebo (n = 27), underwent time and frequency domain and fractal analysis of HR variability, coronary risk variable analyses and quantitative coronary angiograms at baseline and after three years' follow-up. RESULTS: Twenty-four hour standard deviation of sinus intervals (SDNN) decreased from 113 +/- 35 to 94 +/- 30 msec (P < 0.001) during the three year period. Low frequency power spectral component and short-term fractal scaling exponent also decreased (P < 0.001 and P < 0.05, respectively). The reduction of SDNN was weakly related to a change in the triglyceride level (r = -0.33, P < 0.05), glucose level (r = -0.28, P < 0.05) and total cholesterol concentration (r = -0.35, P < 0.01). Furthermore, the reduction of SDNN was related to a decrease in the minimum lumen and mean segment diameter of the coronary arteries (r = 0.36, P < 0.01, and r = 0.39, P < 0.01, respectively). This association was more marked in the placebo group (r = 0.50, P < 0.01 and r = 0.44, P < 0.05, respectively) than among the patients randomized to fenofibrate (not significant for both). CONCLUSIONS: Cardiovascular autonomic regulation assessed by HR variability deteriorates rapidly in type II diabetic subjects with CAD during the time course. Impairment in HR variability is associated with changes in common coronary risk variables and with a progression of CAD.
No takes yet. Share an insight, caveat, or question.
Jokinen et al. (2003) conducted an RCT in Type II diabetes with coronary artery disease (n=53). Fenofibrate vs. Placebo was evaluated on Temporal changes in cardiovascular autonomic regulation assessed by 24-hour heart rate variability (SDNN) (p=<0.001). Fenofibrate attenuated the correlation between reduced heart rate variability (SDNN) and coronary artery disease progression observed in the placebo group (r=0.50, P<0.01 vs not significant).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: